Previously, the goal for BPH management was to remove as much adenomatous tissue as possible. While potentially effective, this may lead to unwanted side effects. There has been a recent paradigm shift for new minimally invasive surgical therapies (MIST) that strategically treat adenomatous tissue, adding potential complexity in managing patients with new or residual symptoms in the postoperative setting. There is a paucity of literature to guide optimal workup and care of patients with persistent LUTS after surgical management. We characterize patients into distinct groups, defined by types of symptoms, irritative versus obstructive, and timing of the symptomatology, short term versus long term. By embracing this patient-centered approach with shared decision management, clinicians can optimize outcomes efficiently improving their patients' quality of life.
Keyphrases
- lower urinary tract symptoms
- minimally invasive
- benign prostatic hyperplasia
- ejection fraction
- newly diagnosed
- prognostic factors
- palliative care
- systematic review
- type diabetes
- physical activity
- patients undergoing
- patient reported outcomes
- coronary artery disease
- climate change
- depressive symptoms
- quality improvement
- coronary artery bypass
- sleep quality
- human health
- surgical site infection